Regulatory, integrative and comparative physiology 300, R11261133, doi: 10.1152/ajpregu.00687.2010 (2011)
Phase 2: Structured Self-Checking Keep a diary
Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe
Additionally, the 5 mg tirzepatide dose, an approved dose for the treatment of T2D that produced substantial reductions in bodyweight, was not evaluated in the SURMOUNT-2 trial
Take Action For questions about GLP-1 medications and overdoses, call Poison Help at 1-800-222-1222
Active Immunisation ACI-7104.056, an adjuvanted protein peptide conjugate vaccine, is currently under investigation at different doses in a phase 2 placebo-controlled trial (NCT06015841), with positive interim results reported by the company in November 2024 [101] but no peer-reviewed publication yet